Parkinson’s disease (PD) is a neurodegenerative disorder associated with multiple comorbidities, including seborrheic dermatitis (SD), which develops in more than half of PD patients. SD in patients with PD can be severe and frequently intractable by traditional topical therapy. Cannabinoids possess anti-inflammatory and neuromodulatory properties working within the intrinsic endocannabinoid system, the activation of which may alleviate the motor symptoms of PD. The effect of cannabinoids on SD is unknown. Here we explore the pathophysiological mechanisms and possible therapeutic role of oral cannabinoids in PD patients with SD, and review speculative mechanisms underlying the association of PD and SD. Current data supporting the use of cannabinoids in both PD and SD, as well as oral cannabinoid safety and tolerability, are presented. Cannabinoids may provide the possibility of simultaneous treatment of both SD and PD. Specific SD studies and additional safety data on oral cannabinoids are needed.

1.
Schapira
AH
,
Jenner
P
.
Etiology and pathogenesis of Parkinson’s disease
.
Mov Disord
.
2011
May
;
26
(
6
):
1049
55
.
[PubMed]
0885-3185
2.
Goldman
JG
,
Postuma
R
.
Premotor and nonmotor features of Parkinson’s disease
.
Curr Opin Neurol
.
2014
Aug
;
27
(
4
):
434
41
.
[PubMed]
1350-7540
3.
Gregory
R
,
Miller
S
.
Parkinson’s disease and the skin
.
Pract Neurol
.
2015
Aug
;
15
(
4
):
246
9
.
[PubMed]
1474-7758
4.
Antunes
I
,
Purim
KSM
,
Grande
LL
,
Alberton
NC
,
Navarro
TFR
,
Winckler
TCD
.
Dermatoses in parkinsonism: the importance of multidisciplinary follow-up.
Rev Assoc Med Bras (1992).
2019
;65(6):791-795.
5.
Arsic Arsenijevic
VS
,
Milobratovic
D
,
Barac
AM
,
Vekic
B
,
Marinkovic
J
,
Kostic
VS
.
A laboratory-based study on patients with Parkinson’s disease and seborrheic dermatitis: the presence and density of Malassezia yeasts, their different species and enzymes production
.
BMC Dermatol
.
2014
Mar
;
14
(
1
):
5
.
[PubMed]
1471-5945
6.
Borda
LJ
,
Wikramanayake
TC
.
Seborrheic Dermatitis and Dandruff: A Comprehensive Review
.
J Clin Investig Dermatol
.
2015
Dec
;
3
(
2
):
[PubMed]
2373-1044
7.
Ashbee
HR
,
Evans
EG
.
Immunology of diseases associated with Malassezia species
.
Clin Microbiol Rev
.
2002
Jan
;
15
(
1
):
21
57
.
[PubMed]
0893-8512
8.
Dessinioti
C
,
Katsambas
A
.
Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies
.
Clin Dermatol
.
2013
Jul-Aug
;
31
(
4
):
343
51
.
[PubMed]
0738-081X
9.
Karimkhani
C
,
Dellavalle
RP
,
Coffeng
LE
,
Flohr
C
,
Hay
RJ
,
Langan
SM
, et al.
Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013
.
JAMA Dermatol
.
2017
May
;
153
(
5
):
406
12
.
[PubMed]
2168-6068
10.
Seborrheic Dermatitis by the Numbers Elsevier Published
.
2017
. Updated 05/05/2018. Accessed2020.
11.
Ooi
ET
,
Tidman
MJ
.
Improving the management of seborrhoeic dermatitis.
Practitioner.
2014
;258(1768):23-26, 23.
12.
Elmariah
SB
.
Adjunctive Management of Itch in Atopic Dermatitis
.
Dermatol Clin
.
2017
Jul
;
35
(
3
):
373
94
.
[PubMed]
0733-8635
13.
Eagleston
LR
,
Kalani
NK
,
Patel
RR
,
Flaten
HK
,
Dunnick
CA
,
Dellavalle
RP
.
Cannabinoids in dermatology: a scoping review
.
Dermatol Online J
.
2018
Jun
;
24
(
6
):
13030/qt7pn8c0sb
.
[PubMed]
1087-2108
14.
More
SV
,
Choi
DK
.
Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection
.
Mol Neurodegener
.
2015
Apr
;
10
(
1
):
17
17
.
[PubMed]
1750-1326
15.
Laurence
M
,
Benito-León
J
,
Calon
F
.
Malassezia and Parkinson’s Disease
.
Front Neurol
.
2019
Jul
;
10
:
758
758
.
[PubMed]
1664-2295
16.
Trinh
J
,
Farrer
M
.
Advances in the genetics of Parkinson disease
.
Nat Rev Neurol
.
2013
Aug
;
9
(
8
):
445
54
.
[PubMed]
1759-4758
17.
Yu
M
,
Arshad
M
,
Wang
W
,
Zhao
D
,
Xu
L
,
Zhou
L
.
LRRK2 mediated Rab8a phosphorylation promotes lipid storage
.
Lipids Health Dis
.
2018
Feb
;
17
(
1
):
34
.
[PubMed]
1476-511X
18.
Narendra
D
,
Walker
JE
,
Youle
R
.
Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism.
Cold Spring Harb Perspect Biol.
2012
;4(11). doi:. Accessed 2012/11//.
19.
Cole
NB
,
Murphy
DD
,
Grider
T
,
Rueter
S
,
Brasaemle
D
,
Nussbaum
RL
.
Lipid droplet binding and oligomerization properties of the Parkinson’s disease protein alpha-synuclein
.
J Biol Chem
.
2002
Feb
;
277
(
8
):
6344
52
.
[PubMed]
0021-9258
20.
Khan
MI
,
Sobocińska
AA
,
Czarnecka
AM
,
Król
M
,
Botta
B
,
Szczylik
C
.
The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
.
Curr Pharm Des
.
2016
;
22
(
12
):
1756
66
.
[PubMed]
1381-6128
21.
Kaur
R
,
Ambwani
SR
,
Singh
S
.
Endocannabinoid System: A Multi-Facet Therapeutic Target
.
Curr Clin Pharmacol
.
2016
;
11
(
2
):
110
7
.
[PubMed]
1574-8847
22.
Hashim
PW
,
Cohen
JL
,
Pompei
DT
,
Goldenberg
G
.
Topical cannabinoids in dermatology
.
Cutis
.
2017
Jul
;
100
(
1
):
50
2
.
[PubMed]
2326-6929
23.
Fakhoury
M
.
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia
.
Mol Neurobiol
.
2017
Jan
;
54
(
1
):
768
78
.
[PubMed]
0893-7648
24.
Vinod
KY
,
Hungund
BL
.
Role of the endocannabinoid system in depression and suicide
.
Trends Pharmacol Sci
.
2006
Oct
;
27
(
10
):
539
45
.
[PubMed]
0165-6147
25.
Paloczi
J
,
Varga
ZV
,
Hasko
G
,
Pacher
P
.
Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation
.
Antioxid Redox Signal
.
2018
Jul
;
29
(
1
):
75
108
.
[PubMed]
1523-0864
26.
Orgado
JM
,
Fernández-Ruiz
J
,
Romero
J
.
The endocannabinoid system in neuropathological states
.
Int Rev Psychiatry
.
2009
Apr
;
21
(
2
):
172
80
.
[PubMed]
0954-0261
27.
Fernández-Ruiz
J
.
The endocannabinoid system as a target for the treatment of motor dysfunction
.
Br J Pharmacol
.
2009
Apr
;
156
(
7
):
1029
40
.
[PubMed]
0007-1188
28.
Sieradzan
KA
,
Fox
SH
,
Hill
M
,
Dick
JP
,
Crossman
AR
,
Brotchie
JM
.
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study
.
Neurology
.
2001
Dec
;
57
(
11
):
2108
11
.
[PubMed]
0028-3878
29.
Chagas
MH
,
Zuardi
AW
,
Tumas
V
,
Pena-Pereira
MA
,
Sobreira
ET
,
Bergamaschi
MM
, et al.
Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial
.
J Psychopharmacol
.
2014
Nov
;
28
(
11
):
1088
98
.
[PubMed]
0269-8811
30.
Carroll
CB
,
Bain
PG
,
Teare
L
,
Liu
X
,
Joint
C
,
Wroath
C
, et al.
Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study
.
Neurology
.
2004
Oct
;
63
(
7
):
1245
50
.
[PubMed]
0028-3878
31.
Maureen
L
.
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson’s Disease
. https://ClinicalTrials.gov/show/NCT03582137. Published
2020
. Accessed July 6th, 2020
32.
Mayser
P
,
Schulz
S
.
Precipitation of free fatty acids generated by Malassezia - a possible explanation for the positive effects of lithium succinate in seborrhoeic dermatitis
.
J Eur Acad Dermatol Venereol
.
2016
Aug
;
30
(
8
):
1384
9
.
[PubMed]
0926-9959
33.
Gupta
AK
,
Bluhm
R
.
Seborrheic dermatitis
.
J Eur Acad Dermatol Venereol
.
2004
Jan
;
18
(
1
):
13
26
.
[PubMed]
0926-9959
34.
Das
J
,
Majumdar
M
,
Chakraborty
U
,
Majumdar
V
,
Mazumdar
G
,
Nath
J
.
Oral itraconazole for the treatment of severe seborrhoeic dermatitis
.
Indian J Dermatol
.
2011
Sep-Oct
;
56
(
5
):
515
6
.
[PubMed]
0019-5154
35.
Tóth
KF
,
Ádám
D
,
Bíró
T
,
Oláh
A
.
Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System
.
Molecules
.
2019
Mar
;
24
(
5
):
E918
.
[PubMed]
1420-3049
36.
Thayikkannu
AB
,
Kindo
AJ
,
Veeraraghavan
M
.
Malassezia-Can it be Ignored?
Indian J Dermatol
.
2015
Jul-Aug
;
60
(
4
):
332
9
.
[PubMed]
0019-5154
37.
Oláh
A
,
Tóth
BI
,
Borbíró
I
,
Sugawara
K
,
Szöllõsi
AG
,
Czifra
G
, et al.
Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
.
J Clin Invest
.
2014
Sep
;
124
(
9
):
3713
24
.
[PubMed]
0021-9738
38.
Tóth
BI
,
Szallasi
A
,
Bíró
T
.
Transient receptor potential channels and itch: how deep should we scratch?
Handb Exp Pharmacol
.
2015
;
226
:
89
133
.
[PubMed]
0171-2004
39.
Dobrosi
N
,
Tóth
BI
,
Nagy
G
,
Dózsa
A
,
Géczy
T
,
Nagy
L
, et al.
Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling
.
FASEB J
.
2008
Oct
;
22
(
10
):
3685
95
.
[PubMed]
0892-6638
40.
O’Sullivan
SE
.
An update on PPAR activation by cannabinoids
.
Br J Pharmacol
.
2016
Jun
;
173
(
12
):
1899
910
.
[PubMed]
0007-1188
41.
Spiera
R
,
Hummers
L
,
Chung
L
, et al.
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. Arthritis Rheumatol.
2020
.
42.
Burstein
SH
,
Karst
M
,
Schneider
U
,
Zurier
RB
.
Ajulemic acid: A novel cannabinoid produces analgesia without a “high”
.
Life Sci
.
2004
Aug
;
75
(
12
):
1513
22
.
[PubMed]
0024-3205
43.
Robinson
ES
,
Alves
P
,
Bashir
MM
,
Zeidi
M
,
Feng
R
,
Werth
VP
.
Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro
.
J Invest Dermatol
.
2017
Nov
;
137
(
11
):
2445
7
.
[PubMed]
0022-202X
44.
Werth
VP
,
Hejazi
E
,
Pena
S
, et al.
Comparison of patients with dermatomyositis in a specialty clinic versus clinical trial with anabasum (JBT‐101), a cannabinoid receptor type 2 agonist [abstract]. rthritis Rheumatol.
2017
;68.
45.
Cohen
K
,
Weinstein
AM
.
Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective
.
Front Public Health
.
2018
Jun
;
6
:
162
162
.
[PubMed]
2296-2565
46.
Zheng
D
,
Bode
AM
,
Zhao
Q
,
Cho
YY
,
Zhu
F
,
Ma
WY
, et al.
The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development
.
Cancer Res
.
2008
May
;
68
(
10
):
3992
8
.
[PubMed]
0008-5472
47.
Brown
JD
,
Winterstein
AG
.
Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use
.
J Clin Med
.
2019
Jul
;
8
(
7
):
E989
.
[PubMed]
2077-0383
48.
Stott
C
,
White
L
,
Wright
S
,
Wilbraham
D
,
Guy
G
.
A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers
.
Springerplus
.
2013
May
;
2
(
1
):
236
.
[PubMed]
2193-1801
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.